Aurinia Pharmaceuticals: There's Still Time For Sales Growth

Core Insights - Aurinia Pharmaceuticals Inc.'s sole approved product, Lupkynis, for lupus nephritis treatment, did not show strong revenue growth from Q2'24 to Q3'24 [1] - The stock is nearing Q4'24 earnings, and a potential resumption of sales growth could lead to a rally [1] Company Overview - Aurinia Pharmaceuticals focuses on the development and commercialization of therapies for kidney diseases, particularly lupus nephritis [1] Market Context - The biotech sector is influenced by events such as trial results and NDA/BLA approvals, which can significantly impact stock performance [1]